Clinical Trials in Norway — Country Dashboard | 654 EU Studies

Filter these 654 trials by condition, phase, sponsor and more.

Open in Search →

654 Registered trials

297 Recruiting

292 Completed trials

216 Sponsors active

122 Research sites

Phase III

Phase II

Phase III: 312 Phase II/III: 38 Phase II: 173 Phase I/II: 37 Phase III/IV: 6 Phase IV: 52 Phase I: 9 Phase I (Other): 19 Phase I (FiH): 7 Other: 1

Oversight events in trials active here:

43 serious breaches 171 temporary halts 11 urgent safety measures 19 unexpected events 27 corrective measures across 88 trials

View oversight register →

Top conditions

Non-small cell lung cancer 11 Crohn's disease 7 Colitis ulcerative 6 Plasma cell myeloma refractory 6 Glioblastoma 6 Prostate cancer metastatic 5 Fabry´s disease 5 Ovarian cancer 5 Hepatocellular carcinoma 4 Chronic obstructive pulmonary disease 4 Myelodysplastic syndrome 4 Squamous cell carcinoma of head and neck 4

Top sponsors

Oslo University Hospital HF 73 Merck Sharp & Dohme LLC 43 Helse Bergen HF 26 Boehringer Ingelheim International GmbH 21 AstraZeneca AB 18 Boehringer Ingelheim Espana S.A. 18 Sanofi-Aventis Recherche & Developpement 18 Novartis Pharma AG 16 St. Olavs Hospital HF 16 Celgene Corp. 12 Glaxosmithkline Research & Development Limited 12 Janssen - Cilag International 12

Cities with most trials

All 59 cities →

All trials — page 9

654 total

INtravenous Contrast computed tomography versus native computed tomography in patients with acute Abdomen and impaired Renal functiOn (INCAR… Recruiting

2024-512084-31-00 Phase IV Patients requiring emergency abdominal or body CT with eGFR … University Of Helsinki
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting

2024-517423-40-00 Phase III Metastatic Castration-Resistant Prostate Cancer Merck Sharp & Dohme LLC
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 Phase III small lymphocytic lymphoma (SLL) University Of Cologne
Plasma cell targeting in ME/CFS Recruiting

2024-520094-13-00 Phase II Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Helse Bergen HF
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Phase III Unresectable, Locally Advanced or Metastatic HER2 positive G… Daiichi Sankyo Inc.
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Phase III Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lun… Eli Lilly & Co.
The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind tr… Recruiting

2024-517981-40-00 Phase III Chronic Migraine Oslo University Hospital HF
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Phase III/IV Chron's Disease Takeda Development Center Americas Inc.
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1… Recruiting

2023-508196-36-00 Phase II Follicular lymphoma Karolinska University Hospital
A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting

2024-517147-31-00 Phase I/II Tumours, Gynecological Glaxosmithkline Research & Development Limited
COSENSE-1: A feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemot… Recruiting

2024-517677-25-00 Phase II MSS/pMMR metastatic colorectal cancer St. Olavs Hospital HF
Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting

2024-516030-35-00 Phase III Multiple myeloma Glaxosmithkline Research & Development Limited
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph… Recruiting

2024-515162-13-00 Phase III Eosinophilic Asthma AstraZeneca AB
A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting

2024-515279-37-00 Phase III Relapsed or Refractory and Lenalidomide exposed Multiple Mye… Celgene Corp.
Anticoagulation with apixaban in venous malformations Recruiting

2024-511930-11-00 Phase II Venous malformation Oslo University Hospital HF
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting

2024-513779-42-02 Phase II Cancer Oslo University Hospital HF
Thrombolysis in Factor Xa-inhibitors Trial (SIFT) Recruiting

2023-509907-34-01 Phase III acute ischemic stroke Oslo University Hospital HF
Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting

2024-513443-93-00 Phase II Recurrent Meningioma without local treatment options (Surger… Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity) Recruiting

2023-506289-29-00 Phase IV Obesity Vestfold Hospital Trust
A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting

2024-514306-31-00 Phase III Pyoderma gangrenosum Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
A pilot study of enalapril in venous malformations Recruiting

2023-510076-31-00 Phase II Venous malformation Oslo University Hospital HF
Water absorption in brain of hydrocephalus Recruiting

2024-519933-53-00 Phase III Adult hydrocephalus Oslo University Hospital HF
Intrathecal MRI Contrast for Assessment of CSF Transport Recruiting

2024-519936-18-00 Phase IV CSF disorders Oslo University Hospital HF
A pilot study for optimizing meropenem administration in the intensive care unit – short six times vs. prolonged three times courses daily Recruiting

2024-520030-30-00 Phase III Serious infection requiring broad-spectrum antibiotic Oslo University Hospital HF

Showing 193–216 of 654 trials

← All countries